Somatic oncogenic point mutations in KRAS were proposed to be crucial to progression and drug resistance in 90% of patients with pancreatic ductal adenocarcinoma, a highly metastatic disease with a high mortality rate [44]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.